Sleep apnea weight loss medication and treatment: CPAP, Zepbound and more
The only sleep apnea weight loss medication approved by the FDA is Zepbound (tirzepatide), cleared on 20 December 2024 for moderate to severe obstructive sleep apnea in adults with obesity. In SURMOUNT-OSA it cut breathing events by 25 to 29 an hour on average. CPAP remains the standard treatment, alongside oral appliances, surgery and nerve stimulation.
What it is
Obstructive sleep apnea (OSA) is repeated collapse of the upper airway during sleep. Breathing partly stops (a hypopnea) or fully stops (an apnea) for 10 seconds or longer, oxygen drops, and the brain wakes briefly to reopen the airway (AASM).
Severity is graded by the apnea-hypopnea index (AHI), the average number of those events per hour of sleep (AASM fact sheet):
- Mild: AHI 5 to 15
- Moderate: AHI 15 to 30
- Severe: AHI above 30
Diagnosis needs a sleep study. The AASM's diagnostic guideline accepts either in-lab polysomnography or a technically adequate home sleep apnea test for uncomplicated adults, and says questionnaires alone cannot diagnose OSA. Loud snoring, gasping or choking in sleep, and daytime sleepiness are the usual clues. Central sleep apnea, where the brain fails to signal breathing, is a different condition and is not what Zepbound treats.
Why it matters
OSA is common and mostly missed. The AASM estimates that 80% to 90% of adults with it are undiagnosed, and that breathing symptoms of OSA occur in about 24% of men and 9% of women.
Untreated, it is linked to daytime high blood pressure, stroke, heart disease, insulin resistance and drowsy-driving crashes (AASM fact sheet). Excess weight is one of the strongest risk factors, which is why weight loss sits beside airway treatments rather than replacing them.
Treatment options
| Option | What it is | Evidence | Best for |
|---|---|---|---|
| Positive airway pressure (CPAP) | A bedside machine that blows pressurized air through a mask to hold the airway open all night. | The AASM calls CPAP the standard treatment for moderate to severe OSA and a good option for mild cases (AASM fact sheet). | Most people with moderate or severe OSA, at any weight. |
| Tirzepatide (Zepbound) plus diet and activity | A weekly GIP/GLP-1 injection that treats OSA by reducing body weight. The only medicine with an FDA OSA indication. | SURMOUNT-OSA: AHI fell 25.3 events/hour vs 5.3 on placebo without PAP, and 29.3 vs 5.5 in people using PAP, over 52 weeks (Zepbound label). | Adults with obesity (BMI 30+) and moderate to severe OSA, with or without CPAP. |
| Oral appliance therapy | A custom mouthguard-style device, fitted by a dentist trained in sleep medicine, that holds the lower jaw or tongue forward. | The AASM describes oral appliances as effective for mild to moderate OSA in people who prefer them or cannot use CPAP (AASM fact sheet). | Mild to moderate OSA, or CPAP intolerance. |
| Upper airway stimulation | An implanted device that stimulates the hypoglossal nerve during sleep so the tongue does not fall back and block the airway. | Listed by the AASM among the treatment options alongside PAP, oral appliances and surgery (AASM statement on Zepbound, December 2024). | Selected adults who cannot use CPAP, after evaluation by a sleep surgeon. |
| Airway or jaw surgery | Procedures that remove or reshape tissue in the throat, nose or jaw to widen the airway. | The AASM lists surgery as an option when noninvasive treatments such as CPAP or oral appliances have not worked (AASM fact sheet). | People with a clear anatomic blockage, assessed by an ENT or sleep surgeon. |
| Weight loss through lifestyle change | A reduced-calorie diet and more physical activity, the same counseling every Zepbound trial participant received. | Placebo groups in SURMOUNT-OSA received diet and activity counseling and lost 1.6% to 2.3% of weight, with AHI falling about 5 events/hour (Zepbound label). | Everyone with OSA and excess weight, alongside an airway treatment. |
Approved medications
| Medication | Approved for | Key trial |
|---|---|---|
| Zepbound (tirzepatide) weekly injection | Moderate to severe obstructive sleep apnea in adults with obesity, with diet and activity. Approved 20 Dec 2024 | SURMOUNT-OSA Study 5 (no PAP): AHI −25.3 vs −5.3/hour; remission or mild non-symptomatic OSA 42.2% vs 15.9% at 52 weeks |
| Zepbound (tirzepatide) with ongoing PAP use | Same OSA indication; the label studied people already on PAP in a separate trial | SURMOUNT-OSA Study 6 (on PAP): AHI −29.3 vs −5.5/hour; remission or mild non-symptomatic OSA 50.2% vs 14.3% |
| Wegovy, Saxenda, Foundayo and other weight medicines | Weight management only. None has an OSA indication, although OSA counts as a weight-related condition for eligibility | No OSA-specific pivotal trial on the Wegovy, Saxenda or Foundayo labels |
Where GLP-1 medications fit
Zepbound works on OSA through weight loss; the AASM notes it helps only where sleep apnea is related to obesity. In SURMOUNT-OSA, people lost 17.7% to 19.6% of body weight on average and their AHI roughly halved, from a starting average near 50 events per hour (Zepbound label, Studies 5 and 6). Systolic blood pressure also fell more than with placebo.
What the label does not say matters as much:
- It did not test when, or whether, someone already well controlled on CPAP can stop using it.
- It covers adults with obesity only, not OSA at a healthy weight.
- It is specific to Zepbound. Mounjaro has the same molecule but no OSA indication, and other GLP-1 drugs have none either.
The AASM's December 2024 statement adds that Zepbound is not a replacement for other therapies, and that pairing it with another treatment may be ideal. A useful question for your sleep physician: "Should I keep using CPAP while I lose weight, and when would we retest?"
When to see a doctor in person
Book a sleep evaluation if a bed partner hears you stop breathing, gasp or choke, or if you fall asleep during activities that need attention, such as driving or talking. The AASM links untreated OSA with stroke and drowsy-driving crashes, so these signs need a sleep study before any medicine. Seek urgent care for chest pain or stroke symptoms. If you already use CPAP and your symptoms return, have the mask and pressure checked with your sleep team rather than stopping on your own.
How Temi helps
Temi cannot diagnose sleep apnea, order a sleep study or adjust CPAP. Temi's physicians review requests for compounded semaglutide or tirzepatide for weight management; these are separate, non-FDA-approved preparations, not generic Zepbound, and carry no OSA indication. Our article on GLP-1 eligibility for sleep apnea lists the records a prescriber or insurer may ask for. For Zepbound's OSA approval, work with a sleep physician.
Frequently asked questions
Is there a weight loss medication approved for sleep apnea?
Yes, one. Zepbound (tirzepatide) is FDA-approved to treat moderate to severe obstructive sleep apnea in adults with obesity, used with a reduced-calorie diet and more activity. The approval came on 20 December 2024. No other GLP-1 drug, including Wegovy, Ozempic or Mounjaro, has a sleep apnea indication, even though some share the same active ingredient.
Can Zepbound replace a CPAP machine?
Not automatically. The SURMOUNT-OSA trials did not test whether people well controlled on CPAP can stop it, and the AASM says Zepbound is not a replacement for other therapies. About half of participants reached remission or mild, symptom-free OSA, so many still had sleep apnea after a year. Ask your sleep physician whether and when a repeat sleep study would show if CPAP is still needed.
Does losing weight cure sleep apnea?
It can reduce it a lot but does not cure it for everyone. In SURMOUNT-OSA, losing about 18% to 20% of body weight on tirzepatide halved the AHI on average, and 42% to 50% of participants reached remission or mild, non-symptomatic OSA (Zepbound label). Airway shape, jaw size and age also drive OSA, so some people still need treatment after losing weight.
How long does Zepbound take to work for sleep apnea?
The trials measured their main result at 52 weeks, after a dose increase lasting up to 20 weeks to a maximum tolerated 10 mg or 15 mg (Zepbound label). Because the benefit comes through weight loss, and weight comes off over months, there is no fixed point when breathing improves. A follow-up sleep study, timed with your sleep physician, is how you find out where you stand.
Do I need a sleep study to get Zepbound for sleep apnea?
In practice, yes. The OSA indication covers moderate to severe disease, meaning an AHI of 15 or more, and only a sleep study measures AHI; the AASM says questionnaires cannot diagnose OSA on their own. SURMOUNT-OSA confirmed severity by polysomnography. A prescriber or insurer may ask for the full sleep-study report, your BMI and your treatment history, so keep copies.
What AHI counts as moderate or severe sleep apnea?
Using AASM ranges, an AHI of 5 to 15 events per hour is mild, 15 to 30 is moderate, and above 30 is severe. Zepbound's label defined moderate as 15 to under 30 and severe as 30 or more. Participants in SURMOUNT-OSA started with an average AHI around 50, so most had severe disease.
Sources
- Zepbound (tirzepatide) prescribing information, Eli Lilly (Section 14.2, OSA studies) (checked October 5, 2026)
- Obstructive Sleep Apnea fact sheet, American Academy of Sleep Medicine (checked October 5, 2026)
- Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea (AASM, J Clin Sleep Med 2017) (checked October 5, 2026)
- AASM statement on Zepbound approval for sleep apnea (23 December 2024) (checked October 5, 2026)
- Zepbound approved by FDA as first sleep apnea medication, AASM (checked October 5, 2026)
- AASM obesity management resources for sleep medicine (checked October 5, 2026)
- SURMOUNT-OSA master protocol (NCT05412004), ClinicalTrials.gov (checked October 5, 2026)
- Wegovy (semaglutide) injection and tablets prescribing information, Novo Nordisk (checked October 5, 2026)
Compounded semaglutide and compounded tirzepatide are not FDA-approved generics of the brand-name products. A licensed 503A compounding pharmacy prepares each one for a single prescription.
Get started
Start online, and a licensed physician reviews your request
A short online questionnaire is the first step. No appointments and no insurance needed.
A licensed physician reviews every request. Nothing on this page is a prescription.